Sign In

Richard Mason

Chief Executive Officer at Apollo Therapeutics

Richard Mason is the Chief Executive Officer of Apollo Therapeutics, a portfolio biopharmaceutical company focused on translating fundamental medical research into medicines.13 Here are some key details about Richard Mason:

Professional Background

  • Over 20 years of experience in the biopharmaceutical industry1
  • Previously led Johnson & Johnson Innovation in Europe1
  • Former CEO of XO1, an anticoagulant antibody company, until its acquisition by Janssen in 20151
  • Held executive roles at BTG Plc and Cambridge Antibody Technology Plc, leading M&A and partnering transactions1

Education and Medical Training

  • Received medical degree from St Bartholomew's Hospital Medical College1
  • Holds a degree in immunology from University College London1
  • Trained in internal medicine in London1
  • Fellow of the Royal College of Physicians1

Recent Experience

  • Served on active duty with the British Army in 2020 as part of the UK government's pandemic response1
  • Member of the UK Vaccines Task Force during the COVID-19 pandemic1
  • Became CEO of Apollo Therapeutics in December 20202

Current Role at Apollo Therapeutics

As CEO, Richard Mason leads Apollo Therapeutics in its mission to translate fundamental medical research into medicines using a hub-and-spoke approach.3 The company has raised over $450 million since its inception, including a recent $260 million Series C financing round.3

Richard Mason's LinkedIn username is richardmason1, where he occasionally shares updates about Apollo Therapeutics' collaborations and partnerships.45

Highlights

Jun 16 · linkedin

Happy second birthday Apollo Therapeutics!!! Cannot believe there are over 30 of us in the team now, and almost as many programs. We have come so far as a company in two years and I am so excited about what we are doing together as a team to advance a stellar pipeline of cutting edge therapeutics. Extremely grateful for the support of our awesome investors and university partners and inventors/PIs for helping us to get here. And thank you to the Cawkill Baking Company and their team of biology PhDs for an amazing cake (no actual formulas revealed)! #thankyou #team #patientsquarecapital #psc #rockspringscapital #universityofcambridge #ucl #imperialcollegelondon #kingscollegelondon #icr

Aug 1 · linkedin

Delighted to announce our first in-license/acquisition of a clinical program.

Camoteskimab targets IL-18, a partner-in-crime to IL-1 in various conditions stemming from aberrant activation of inflammasomes. The mAb was discovered by AstraZeneca’s antibody group in Cambridge, formerly known as CAT (Cambridge Antibody Technology) and developed by our friends at Avalo Therapeutics.

It has been a fantastic year of internal progress with growth of our pipeline and development of our team and organisation. Thanks to our university partners University of Cambridge Imperial College London UCL King's College London and our investors Patient Square Capital Rock Springs Capital UCL Technology Fund Reimagined Ventures for their great support.

Onwards!

#biotech #cambridge #cambridgema

Related Questions

What are Richard Mason's key achievements at Apollo Therapeutics?
How did Richard Mason's experience at Johnson & Johnson influence his role at Apollo Therapeutics?
What challenges did Richard Mason face during his time at XO1?
How did Richard Mason contribute to the UK's COVID-19 pandemic response?
What is the strategic direction Richard Mason is leading at Apollo Therapeutics?
R
Add to my network

Location

Cambridge, England, United Kingdom